Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.
Lennox-Gastaut Syndrome (LGS) is a severe, lifelong form of epileptic encephalopathy that presents significant treatment challenges. The management of LGS remains primarily symptomatic. Historically, the effectiveness of traditional antiseizure medications (ASMs) has been limited, prompting practitioners to explore off-label treatments and anecdotal drugs, including medications not originally intended for epilepsy. Although some controlled clinical trials have been conducted, LGS management ofte
Peer-reviewed industrial hemp research by Maria Fernanda Arboleda; Erin Prosk; Alain Watier; Max J. Schmulson published in NeuroGastroLATAM Reviews (2021).
Peer-reviewed industrial hemp research by Nicola Specchio; Stéphane Auvin; T. L. Greco; Lieven Lagae; Charlotte Nortvedt; Sameer M. Zuberi published in CNS Drugs (2025).
Epilepsy is a disorder characterized by abnormal brain neuron activity, predisposing individuals to seizures. The International League Against Epilepsy (ILAE) categorizes epilepsy into the following groups: focal, generalized, generalized and focal, and unknown. Infants are the most vulnerable pediatric group to the condition, with the cause of epilepsy development being attributed to congenital brain developmental defects, white matter damage, intraventricular hemorrhage, perinatal hypoxic-isch
<i>GNAO1</i>-associated disorders have a large spectrum of neurological symptoms, from early-onset developmental and epileptic encephalopathies (DEE) to late-onset movement disorders. First reported in 2013 and now identified in around 400 cases worldwide, this disease is caused by dominant, mostly de novo missense mutations in <i>GNAO1</i>, the gene encoding the major neuronal G protein Gαo. Being the immediate transducer of a number of neuronal G protein-coupled receptors, Gαo plays crucial fu
Epilepsy is a common neurological disorder with a significant burden on patients, and ~30% of cases are resistant to standard antiepileptic treatments. This has led to the exploration of alternative therapies, such as cannabidiol (CBD). Studies suggest that CBD may reduce the frequency and severity of seizures in patients with drug-resistant epilepsy. In addition to clinical monitoring, EEG is frequently used to assess brain function and monitor CBD's effects on seizures, with documented improve
Ketogenic diet can cause acute changes in liver function tests during initiation of ketogenic diet, with both hepatocellular and cholestatic patterns, with and without the concurrent use of hepatotoxic medications. In most patients, ketogenic diet can be continued successfully by making changes to medications or addition of choline.
Peer-reviewed industrial hemp research by Robert-Alexandru Vlad; Andrada Pintea; Paula Antonoaea; Emőke-Margit Rédai; Magdalena Bîrsan; Gabriel Hancu; Lénárd Farczádi; Silvia Imre; Daniela-Lucia Muntean; Tamás Sovány published in Scientific Reports (2025).
O canabidiol (CBD) é um dos fitocanabinoides mais abundantes da planta Cannabis sp., sendo o mais amplamente estudado nos aspectos farmacológicos por ser responsável por muitos dos efeitos terapêuticos da planta. O uso medicinal de derivados da Cannabis sp. é crescente e um dos fatores estimulantes para sua utilização e pesquisa foi a descrição do Sistema Endocanabinoide na década de 90, composto pelos receptores canabinoides (CB1 e CB2), os endocanabinoides endógenos e suas enzimas de síntese e
Cannabis is a plant rich in various compounds that have a variety of impacts on the physiology of humans and the effects of these metabolites have a significant role in managing a variety of clinical diseases. A substantial increase in the use of SC (synthetic cannabinoids) had seen in the last few years especially infrequent cannabis users. The SCs will generate psychoactive effects that were similar to cannabis. However, the composition and pharmacological characteristics of these drugs make t
CADTH recommends that Epidiolex be reimbursed by public drug plans for the adjunctive therapy of seizures associated with Dravet syndrome (DS) in patients aged 2 years or older, if certain conditions are met. Epidiolex should only be covered to treat patients with seizures associated with DS who experience at least 4 convulsive seizures per 28 days and whose seizures are not adequately controlled with 2 or more other antiseizure medications (ASMs). Epidiolex should only be reimbursed if prescrib
During the 3-year observation period, 6% of epileptic patients on ASMs showed one or more ADRs. Carbamazepine was responsible for about a quarter of these reactions, two of which were serious. Half of the ADRs occurred with polytherapy, which often included valproic acid and stiripentol. It is to be hoped that such active pharmacovigilance through the collaboration of hospital pharmacists and physicians will serve to improve the management of treatment.
Medical cannabis (MC) may offer therapeutic benefits for children with complex neurological conditions and chronic diseases. In Canada, parents, and caregivers frequently report encountering barriers when accessing MC for their children. These include negative preconceived notions about risks and benefits, challenges connecting with a knowledgeable healthcare provider (HCP), the high cost of MC products, and navigating MC product shortages. In this manuscript, we explore several of these barrier
Epilepsy is one of the most prevalent chronic medical conditions that really can affect individuals at any age. A broader study of the pathogenesis of the epileptic condition will probably serve as the cornerstone for the development of new antiepileptic remedies that aim to treat epilepsy symptomatically as well as prevent the epileptogenesis process or regulate its progression. Cellular changes in the brain include oxidative stress, neuroinflammation, inflammatory cell invasion, angiogenesis,
Peer-reviewed industrial hemp research by Franziska Hopfner; Carsten Buhmann; Joseph Claßen; Florian Holtbernd; Stephan Klebe; Jiri Koschel; Zacharias Kohl; Sebastian Paus; David J. Pedrosa published in Journal of Neural Transmission (2024).
Creatine transporter deficiency (CRTR-D) is a rare X-linked inherited disease belonging to the group of cerebral creatine deficiency disorders. Major clinical features include developmental delay and epilepsy. To date, fewer than 200 individuals with CRTR-D have been reported. As a result, there is little evidence for effective treatment. Available therapies are creatine precursors, with a mild effect on disease progression. Concerning epilepsy, standard management is recommended and no specific
Peer-reviewed industrial hemp research by Anna Dołoto; Ewelina Bąk; Gabriela Batóg; Iwona Piątkowska‐Chmiel; Mariola Herbet published in Pharmacological Reports (2024).
Precision, or personalized, medicine aims to stratify patients based on variable pathogenic signatures to optimize the effectiveness of disease prevention and treatment. This approach is favorable in the context of brain disorders, which are often heterogeneous in their pathophysiological features, patterns of disease progression and treatment response, resulting in limited therapeutic standard-of-care. Here we highlight the transformative role that human induced pluripotent stem cell (hiPSC)-de
Introduction: Sturge-Weber Syndrome is a rare neurocutaneous disorder characterized by facial port-wine birthmarks, leptomeningeal angiomatosis, and associated neurological, ophthalmological, and dermatological symptoms. The condition's variable presentation poses challenges for diagnosis, management, and long-term care. Advances in imaging, genetics, and targeted therapies are reshaping the landscape of Sturge-Weber Syndrome treatment. Aim of Study: This review aims to summarize current knowled
<b>Background:</b> The pathophysiology of epilepsy is characterized by increased neuronal activity due to an excess of the excitatory neurotransmitter glutamate and a deficiency in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Epilepsy presents with seizures, neuronal loss, and hyperactivity in the subthalamic nucleus (STN). Astrocytes play a crucial role by absorbing extracellular glutamate through glutamate transporter-1 (GLT-1), thereby reducing neuronal excitation. Upregula
Cannabidiol (CBD), a non-psychoactive cannabinoid with therapeutic potential, is increasingly used in combination with other drugs, raising concerns about potential interactions and their impact on safety and efficacy. This scoping review aimed to map the current evidence on CBD interactions across different drug classes and assess their clinical significance. The study followed the Joanna Briggs Institute guidelines, utilizing a structured protocol based on the population, concept, and context